Empathx Clinical Research Joins hyperCORE International Network to Expand Clinical Trial Access

Empathx Clinical Research has become part of hyperCORE International's global partner site network, marking a significant expansion of clinical research capabilities across the United States. The Tampa Bay-based organization operates eight clinical trial sites across six states: California, Florida, Massachusetts, Michigan, Missouri, and Texas. This geographic diversity provides sponsors with access to varied patient populations and enhances the network's ability to conduct comprehensive clinical studies.

The organization specializes in advancing clinical trials across several critical therapeutic areas, including cardio-metabolic disease, central nervous system disorders, nephrology, and infectious disease. Empathx's unique site portfolio combines dedicated research centers with integrated research sites embedded within large, specialized physician practices. This hybrid model brings clinical research directly into care environments where patients already receive treatment, potentially improving trial accessibility and patient participation rates.

CEO Dustin Owen emphasized that joining hyperCORE reflects a shared commitment to collaboration and quality among leading research site networks. Owen previously served as Senior Vice President of Accelerated Enrollment Solutions at Thermo Fisher Scientific/PPD, where he led global clinical research site operations. "Joining hyperCORE is about partnering with like-minded, high quality site networks with similar mission," Owen stated. "The partnership enhances our ability to work with sponsors to bring life-changing therapies to our communities."

Nicholas Focil, President of hyperCORE International, noted that Empathx brings therapeutic expertise, geographic reach, and innovative site integration to the network. "Their approach to embedding research in clinical care aligns with hyperCORE's mission to expand patient access and deliver high-quality trials," Focil said. The partnership strengthens hyperCORE's position as a leading clinical research network with more than 80 active trial sites across five countries.

Collectively, hyperCORE partners have completed over 7,000 studies involving more than 140,000 randomized participants. The network aligns independent organizations around harmonized operational frameworks that support consistent trial execution. This collaboration comes at a time when the clinical research industry faces increasing pressure to improve patient access and diversity in clinical trials. By integrating research into existing clinical care settings, the partnership addresses barriers that often prevent eligible patients from participating in clinical studies.

The expansion of hyperCORE's network through the addition of Empathx Clinical Research represents a strategic move to enhance clinical trial capabilities across multiple therapeutic areas. The partnership's focus on embedding research within clinical care environments could serve as a model for improving patient access and diversity in clinical trials. As the clinical research landscape evolves, such collaborations between established networks and innovative research organizations may become increasingly important for advancing medical research and bringing new therapies to patients more efficiently.